A Phase II Study of Bevacizumab in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck.

Trial Profile

A Phase II Study of Bevacizumab in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jul 2012 Planned end date changed from 1 Dec 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
    • 28 Jun 2011 Planned end date changed from 1 Jan 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 27 Sep 2010 Planned end date changed from 1 Sep 2008 to 1 Jan 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top